RA Capital Management
Latest statistics and disclosures from Ra Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ASND, PCVX, LEGN, JANX, AVTE, and represent 38.97% of Ra Capital Management's stock portfolio.
- Added to shares of these 10 stocks: EWTX (+$163M), DYN (+$141M), EVH (+$105M), LENZ (+$93M), LBPH (+$71M), DNTH (+$70M), ATXS (+$62M), CGON (+$61M), TYRA (+$52M), PRAX (+$51M).
- Started 21 new stock positions in ATXS, BOLD, PRAX, RGLS, CRVO, ACET, MGX, LXEO, SERA, EYPT. ANRO, CGON, EWTX, LBPH, LRMR, DYN, CYBN, VXRT, DNTH, IMTX, LENZ.
- Reduced shares in these 10 stocks: , Cymabay Therapeutics (-$164M), Icosavax (-$94M), Alpine Immune Sciences (-$94M), Inhibrx (-$73M), MGNX (-$29M), TSHA (-$22M), Harpoon Therapeutics (-$17M), CMPS, CNTB.
- Sold out of its positions in Alpine Immune Sciences, CNTB, Cymabay Therapeutics, Harpoon Therapeutics, Icosavax, ImmunoGen, SABS.
- Ra Capital Management was a net buyer of stock by $280M.
- Ra Capital Management has $7.9B in assets under management (AUM), dropping by 22.77%.
- Central Index Key (CIK): 0001346824
Tip: Access up to 7 years of quarterly data
Positions held by RA Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv![Download consolidated filings csv](/static/img/csv.png)
![Download consolidated filings xlsx](/static/img/microsoft-excel.png)
Portfolio Holdings for Ra Capital Management
Ra Capital Management holds 76 positions in its portfolio as reported in the March 2024 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Ascendis Pharma A/s - SH (ASND) | 19.4 | $1.5B | 10M | 151.17 |
|
|
Vaxcyte SH (PCVX) | 7.1 | $560M | +3% | 8.2M | 68.31 |
|
Legend Biotech Corp- SH (LEGN) | 4.9 | $385M | +9% | 6.9M | 56.09 |
|
Janux Therapeutics SH (JANX) | 4.4 | $345M | 9.2M | 37.65 |
|
|
Aerovate Therapeutics SH (AVTE) | 3.1 | $244M | 8.3M | 29.57 |
|
|
Rhythm Pharmaceuticals SH (RYTM) | 2.9 | $231M | 5.3M | 43.33 |
|
|
Evolent Health Inc - A SH (EVH) | 2.4 | $188M | +125% | 5.7M | 32.79 |
|
Newamsterdam Pharma Co Nv SH (NAMS) | 2.4 | $186M | 7.9M | 23.65 |
|
|
Rxsight SH (RXST) | 2.3 | $178M | 3.4M | 51.58 |
|
|
Tyra Biosciences SH (TYRA) | 2.2 | $171M | +43% | 10M | 16.40 |
|
Edgewise Therapeutics SH (EWTX) | 2.1 | $163M | NEW | 8.9M | 18.24 |
|
4d Molecular Therapeutics In SH (FDMT) | 2.0 | $161M | +21% | 5.1M | 31.86 |
|
Biogen SH (BIIB) | 2.0 | $160M | +39% | 741k | 215.63 |
|
Pepgen SH (PEPG) | 2.0 | $157M | +31% | 11M | 14.70 |
|
Geron Corp SH (GERN) | 1.9 | $153M | 46M | 3.30 |
|
|
89bio SH (ETNB) | 1.9 | $149M | +11% | 13M | 11.64 |
|
Dyne Therapeutics SH (DYN) | 1.8 | $141M | NEW | 5.0M | 28.39 |
|
Apogee Therapeutics SH (APGE) | 1.7 | $131M | 2.0M | 66.45 |
|
|
Day One Biopharmaceuticals I SH (DAWN) | 1.6 | $129M | 7.8M | 16.52 |
|
|
Nkarta SH (NKTX) | 1.5 | $117M | +38% | 11M | 10.81 |
|
Wave Life Sciences SH (WVE) | 1.4 | $112M | 18M | 6.17 |
|
|
Ars Pharmaceuticals SH (SPRY) | 1.4 | $111M | +14% | 11M | 10.22 |
|
Fulcrum Therapeutics SH (FULC) | 1.4 | $110M | 12M | 9.44 |
|
|
Verona Pharma Plc - SH (VRNA) | 1.3 | $102M | 6.3M | 16.09 |
|
|
Lenz Therapeutics SH (LENZ) | 1.2 | $93M | NEW | 4.2M | 22.33 |
|
Inhibrx SH | 1.2 | $92M | -44% | 2.6M | 34.96 |
|
Avidity Biosciences SH (RNA) | 1.1 | $84M | +33% | 3.3M | 25.52 |
|
Axsome Therapeutics SH (AXSM) | 1.0 | $80M | 1.0M | 79.80 |
|
|
Longboard Pharmaceuticals In SH (LBPH) | 0.9 | $71M | NEW | 3.3M | 21.60 |
|
Dianthus Therapeutics SH (DNTH) | 0.9 | $70M | NEW | 2.3M | 30.00 |
|
Gh Research SH (GHRS) | 0.8 | $67M | +11% | 6.3M | 10.66 |
|
Structure Therapeutics SH (GPCR) | 0.8 | $65M | +210% | 1.5M | 42.86 |
|
Mineralys Therapeutics SH (MLYS) | 0.8 | $63M | +52% | 4.9M | 12.91 |
|
Astria Therapeutics SH (ATXS) | 0.8 | $62M | NEW | 4.4M | 14.07 |
|
Cg Oncology SH (CGON) | 0.8 | $61M | NEW | 1.4M | 43.90 |
|
Acumen Pharmaceuticals SH (ABOS) | 0.8 | $61M | 15M | 4.05 |
|
|
Iteos Therapeutics SH (ITOS) | 0.8 | $60M | 4.4M | 13.64 |
|
|
Solid Biosciences SH (SLDB) | 0.7 | $58M | +26% | 4.3M | 13.32 |
|
Madrigal Pharmaceuticals SH (MDGL) | 0.7 | $55M | 205k | 267.04 |
|
|
Vor Biopharma SH (VOR) | 0.7 | $54M | 23M | 2.37 |
|
|
Praxis Precision Medicines I SH (PRAX) | 0.6 | $51M | NEW | 828k | 61.02 |
|
Urogen Pharma SH (URGN) | 0.6 | $46M | 3.1M | 15.00 |
|
|
Larimar Therapeutics SH (LRMR) | 0.6 | $46M | NEW | 6.0M | 7.59 |
|
Cytek Biosciences SH (CTKB) | 0.6 | $46M | 6.8M | 6.71 |
|
|
C4 Therapeutics SH (CCCC) | 0.5 | $40M | 4.9M | 8.17 |
|
|
Werewolf Therapeutics SH (HOWL) | 0.5 | $40M | 6.1M | 6.48 |
|
|
Enliven Therapeutics SH (ELVN) | 0.5 | $37M | 2.1M | 17.59 |
|
|
Eliem Therapeutics SH (ELYM) | 0.5 | $36M | 13M | 2.74 |
|
|
Acrivon Therapeutics SH (ACRV) | 0.4 | $34M | 4.8M | 7.15 |
|
|
Taysha Gene Therapies SH (TSHA) | 0.4 | $31M | -41% | 11M | 2.87 |
|
Boundless Bio SH (BOLD) | 0.4 | $31M | NEW | 2.2M | 14.25 |
|
Macrogenics SH (MGNX) | 0.4 | $31M | -48% | 2.1M | 14.72 |
|
Tenaya Therapeutics SH (TNYA) | 0.4 | $30M | +4% | 5.8M | 5.23 |
|
Cybin SH (CYBN) | 0.3 | $24M | NEW | 58M | 0.41 |
|
Alto Neuroscience SH (ANRO) | 0.3 | $21M | NEW | 1.4M | 15.35 |
|
Cervomed SH (CRVO) | 0.3 | $20M | NEW | 862k | 23.30 |
|
Vaxart SH (VXRT) | 0.3 | $20M | NEW | 15M | 1.30 |
|
Bicycle Therapeutics Plc- SH (BCYC) | 0.3 | $20M | 800k | 24.90 |
|
|
Eyepoint Pharmaceuticals SH (EYPT) | 0.2 | $19M | NEW | 939k | 20.67 |
|
Third Harmonic Bio SH (THRD) | 0.2 | $19M | 2.0M | 9.44 |
|
|
Pliant Therapeutics SH (PLRX) | 0.2 | $19M | 1.3M | 14.90 |
|
|
Sera Prognostics Inc-a SH (SERA) | 0.2 | $18M | NEW | 2.0M | 9.10 |
|
Metagenomi SH (MGX) | 0.2 | $18M | NEW | 1.7M | 10.55 |
|
Immatics Nv SH (IMTX) | 0.2 | $18M | NEW | 1.8M | 10.51 |
|
An2 Therapeutics SH (ANTX) | 0.2 | $18M | 5.6M | 3.25 |
|
|
Regulus Therapeutics SH (RGLS) | 0.2 | $18M | NEW | 6.3M | 2.88 |
|
Black Diamond Therapeutics I SH (BDTX) | 0.2 | $18M | 3.5M | 5.07 |
|
|
Adicet Bio SH (ACET) | 0.2 | $18M | NEW | 7.5M | 2.35 |
|
Arvinas SH (ARVN) | 0.2 | $17M | 421k | 41.28 |
|
|
Lexeo Therapeutics SH (LXEO) | 0.1 | $10M | NEW | 661k | 15.68 |
|
Chimerix SH (CMRX) | 0.1 | $9.3M | 8.8M | 1.06 |
|
|
Igm Biosciences SH (IGMS) | 0.1 | $9.0M | 938k | 9.65 |
|
|
Compass Pathways SH (CMPS) | 0.1 | $6.6M | -38% | 791k | 8.32 |
|
Curevac Nv SH (CVAC) | 0.1 | $6.0M | -28% | 2.0M | 3.03 |
|
Unicycive Therapeutics SH (UNCY) | 0.1 | $4.8M | 3.5M | 1.38 |
|
|
Newamsterdam Pharma Co Nv-27 SH (NAMSW) | 0.0 | $3.7M | 333k | 11.04 |
|
Past Filings by Ra Capital Management
SEC 13F filings are viewable for Ra Capital Management going back to 2010
- Ra Capital Management 2024 Q1 amended filed May 17, 2024
- Ra Capital Management 2024 Q1 filed May 15, 2024
- Ra Capital Management 2023 Q4 filed Feb. 14, 2024
- Ra Capital Management 2023 Q3 amended filed Nov. 15, 2023
- Ra Capital Management 2023 Q3 filed Nov. 14, 2023
- Ra Capital Management 2023 Q2 filed Aug. 14, 2023
- Ra Capital Management 2023 Q1 filed May 15, 2023
- Ra Capital Management 2022 Q4 filed Feb. 14, 2023
- Ra Capital Management 2022 Q3 filed Nov. 14, 2022
- Ra Capital Management 2022 Q2 filed Aug. 15, 2022
- Ra Capital Management 2022 Q1 filed May 16, 2022
- Ra Capital Management 2021 Q4 filed Feb. 14, 2022
- Ra Capital Management 2021 Q3 filed Nov. 15, 2021
- Ra Capital Management 2021 Q2 filed Aug. 16, 2021
- Ra Capital Management 2021 Q1 filed May 17, 2021
- Ra Capital Management 2020 Q4 filed Feb. 16, 2021